What price a diagnosis?

Developmental Medicine and Child Neurology

Volumn 53, Issue 11, 2011, Pages 971-

  Lynch, Sally Ann ^a  

^a OUR LADY S CHILDREN S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CHILD; CHROMOSOME ANALYSIS; COPY NUMBER VARIATION; COST BENEFIT ANALYSIS; DEVELOPMENTAL DISORDER; DIAGNOSTIC VALUE; GENETIC SCREENING; HUMAN; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SCREENING TEST;

COST-BENEFIT ANALYSIS; DEVELOPMENTAL DISABILITIES; FEMALE; GENETIC TESTING; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 80054947488     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2011.04085.x     Document Type: Note

References (4)

1. Roeleveld N, Zielhuis GA, Gabreëls F. The prevalence of mental retardation: a critical review of recent literature. Dev Med Child Neurol 1997; 39: 125-32.
2. Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010; 86: 749-64.
3. Lenhard W, Breitenbach E, Ebert H, Schindelhauer-Deutscher HJ, Henn W. Psychological benefit of diagnostic certainty for mothers of children with disabilities: lessons from Down syndrome. Am J Med Genet 2005; 133: 170-5.
4. Trakadis Y, Shevell M. Microarray as a first genetic test in global developmental delay a cost-effectiveness analysis. Dev Med Child Neurol 2011; Doi: (Published online).